- $10.72bn
- $9.81bn
- $396.29m
Annual income statement for Astera Labs, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | 10-K |
| Standards: | USG | USG | USG |
| Status: | Final | Final | Final |
| Revenue | |||
| Total Revenue | 79.9 | 116 | 396 |
| Cost of Revenue | |||
| Gross Profit | 58.7 | 79.8 | 303 |
| Selling / General / Administrative Expenses | |||
| Research And Development | |||
| Total Operating Expenses | 140 | 145 | 512 |
| Operating Profit | -60.2 | -29.5 | -116 |
| Total Net Non Operating Interest Income / Expense | |||
| Net Income Before Taxes | -57.6 | -22.9 | -81.8 |
| Provision for Income Taxes | |||
| Net Income After Taxes | -58.3 | -26.3 | -83.4 |
| Net Income Before Extraordinary Items | |||
| Net Income | -58.3 | -26.3 | -83.4 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||
| Income Available to Common Shareholders Including Extraordinary Items | |||
| Diluted Net Income | -58.3 | -26.3 | -83.4 |
| Diluted Weighted Average Shares | |||
| Basic EPS Including Extraordinary Items | |||
| Diluted EPS Including Extraordinary Items | |||
| Diluted EPS Excluding Extraordinary Items | |||
| Normalised Income Before Taxes | |||
| Normalised Income After Taxes | |||
| Normalised Income Available to Common Shareholders | |||
| Diluted Normalised EPS | -0.383 | -0.172 | -0.636 |
| Dividends per Share |